Korea Research Institute of Chemical Technology (KRICT) and PINOTBIO have patented benzothiazole and benzimidazole derivatives acting as NAD-dependent protein deacetylase sirtuin-7 (SIRT7) inhibitors reported to be useful for the treatment of cancer, among other disorders.

PharminoGen has presented prazole-carboxamide derivatives acting as cannabinoid CB1 receptor antagonists reported to be useful for the treatment of non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, dyslipidemia and diabetes.

Scientists have discovered that the enzyme aconitate decarboxylase 1 (ACOD1) is not an anti-inflammatory mediator in sepsis.

Noninvasive electrical stimulation of the brain for 20 minutes per session over 4 days has been demonstrated to improve both working- and long-term memory for at least 1 month, in people aged 65-88 years.

China's National Medical Products Administration (NMPA) has cleared an IND for CM-369, an anti-CC chemokine receptor 8 (CCR8) monoclonal antibody, developed by Tiannuojiancheng Pharma, a joint venture between InnoCare Pharma and Keymed Biosciences.

Researchers at the University of Washington and the Fred Hutchinson Cancer Center have reported the development of an in vivo model of macrophage infiltration of the tumor microenvironment (TME) in melanoma and how infiltration affects tumor progression.

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and > 80% of cases are associated with the most common risk factor of liver cirrhosis.

Because dysregulated energy metabolism is common across both familial and sporadic forms of amyotrophic lateral sclerosis (ALS), targeting energy production is believed to have therapeutic potential. University of Edinburgh and University of Oxford researchers have tested modulating the expression of the glycolysis enzyme phosphoglycerate kinase 1 (PGK1) in preclinical models of ALS by using terazosin, a PGK1 activator, with the aim of confirming it as a therapeutic target in the treatment of the disease.

The FDA has granted rare pediatric disease designation to iECURE's lead product candidate GTP-506 for the treatment of ornithine transcarbamylase (OTC) deficiency in a pediatric population.

Parkinson's disease (PD) is the second most common neurodegenerative disorder and is characterized by the progressive loss of dopaminergic neurons in the substantia nigra and the abnormal accumulation and aggregation of alpha-synuclein.